Development and characterization of Anti-VLA4 Monoclonal Antibody as a potential biopharmaceutical for the treatment of Multiple Sclerosis

Detalhes bibliográficos
Autor(a) principal: Castro, Vitória Fernandes de
Data de Publicação: 2023
Outros Autores: Aquino, Carolina Lessa, Lima, Erykson, Chaves, Beatriz, Reis, Rafaella, Almeida, Vinícius Cotta de, Esteves, Gabriela Santos, Medeiros, Marco Alberto
Tipo de documento: Artigo de conferência
Idioma: eng
Título da fonte: Repositório Institucional da FIOCRUZ (ARCA)
Texto Completo: https://www.arca.fiocruz.br/handle/icict/57932
Resumo: Apresentador do material: Vitória Fernandes de Castro Tipo de material apresentado: Pôster
id CRUZ_952b5cc57a063ce959054c57dc584dd7
oai_identifier_str oai:www.arca.fiocruz.br:icict/57932
network_acronym_str CRUZ
network_name_str Repositório Institucional da FIOCRUZ (ARCA)
repository_id_str 2135
spelling Castro, Vitória Fernandes deAquino, Carolina LessaLima, EryksonChaves, BeatrizReis, RafaellaAlmeida, Vinícius Cotta deEsteves, Gabriela SantosMedeiros, Marco Alberto2023-04-24T14:04:43Z2023-04-24T14:04:43Z2023CASTRO, V. F. de et al. Development and characterization of Anti-VLA4 Monoclonal Antibody as a potential biopharmaceutical for the treatment of Multiple Sclerosis. In: INTERNATIONAL SYMPOSIUM ON IMMUNOBIOLOGICALS, 7., 2023, Rio de Janeiro. Annals of the Symposium: building pathways to accelerated the development of the national tecnhnological innovation ecosystem. Rio de Janeiro: Instituto de Tecnologia em Imunobiológicos, 2023. p. 42.https://www.arca.fiocruz.br/handle/icict/5793210.35259/isi.2023_57932Apresentador do material: Vitória Fernandes de Castro Tipo de material apresentado: PôsterOs autores externos submeteram sua publicação para apresentação de trabalho no evento “International Symposium on Immunobiologicals”, que foi coordenado e organizado pelo Instituto de Tecnologia em Imunobiológicos (Bio-Manguinhos), da Fundação Oswaldo Cruz.Fundação Oswaldo Cruz. Instituto de Tecnologia em Imunobiológicos. Rio de Janeiro, RJ, Brasil.Fundação Oswaldo Cruz. Instituto de Tecnologia em Imunobiológicos. Rio de Janeiro, RJ, Brasil.Fundação Oswaldo Cruz. Instituto de Tecnologia em Imunobiológicos. Rio de Janeiro, RJ, Brasil.Fiocruz/Ceará.Fundação Oswaldo Cruz. Instituto Oswaldo Cruz. Rio de Janeiro, RJ, Brasil.Fundação Oswaldo Cruz. Instituto Oswaldo Cruz. Rio de Janeiro, RJ, Brasil.Fundação Oswaldo Cruz. Instituto de Tecnologia em Imunobiológicos. Rio de Janeiro, RJ, Brasil.Fundação Oswaldo Cruz. Instituto de Tecnologia em Imunobiológicos. Rio de Janeiro, RJ, Brasil.Fundação Oswaldo Cruz. Instituto de Tecnologia em Imunobiológicos. Rio de Janeiro, RJ, Brasil.Fundação Oswaldo Cruz. Instituto de Tecnologia em Imunobiológicos. Rio de Janeiro, RJ, Brasil.Fundação Oswaldo Cruz. Instituto de Tecnologia em Imunobiológicos. Rio de Janeiro, RJ, Brasil.Fiocruz/Ceará.Fundação Oswaldo Cruz. Instituto Oswaldo Cruz. Rio de Janeiro, RJ, Brasil.Fundação Oswaldo Cruz. Instituto Oswaldo Cruz. Rio de Janeiro, RJ, Brasil.Fundação Oswaldo Cruz. Instituto de Tecnologia em Imunobiológicos. Rio de Janeiro, RJ, Brasil.Fundação Oswaldo Cruz. Instituto de Tecnologia em Imunobiológicos. Rio de Janeiro, RJ, Brasil.engEsclerose MúltiplaBioterapêuticoAnticorpos MonoclonaisMultiple SclerosisBiotherapeuticMonoclonal AntibodiesEsclerose MúltiplaAnticorpos MonoclonaisDevelopment and characterization of Anti-VLA4 Monoclonal Antibody as a potential biopharmaceutical for the treatment of Multiple Sclerosisinfo:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/conferenceObjectinfo:eu-repo/semantics/openAccessreponame:Repositório Institucional da FIOCRUZ (ARCA)instname:Fundação Oswaldo Cruz (FIOCRUZ)instacron:FIOCRUZLICENSElicense.txttext/plain1748https://www.arca.fiocruz.br/bitstream/icict/57932/1/license.txt8a4605be74aa9ea9d79846c1fba20a33MD51ORIGINALAnais7thISI2023_42.pdfAnais7thISI2023_42.pdfapplication/pdf177891https://www.arca.fiocruz.br/bitstream/icict/57932/2/Anais7thISI2023_42.pdf65f50a1690fe13e05b6a0fd850c93ccbMD52icict/579322023-04-26 16:55:56.501oai:www.arca.fiocruz.br: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Repositório InstitucionalPUBhttps://www.arca.fiocruz.br/oai/requestrepositorio.arca@fiocruz.bropendoar:21352023-04-26T19:55:56Repositório Institucional da FIOCRUZ (ARCA) - Fundação Oswaldo Cruz (FIOCRUZ)false
dc.title.en_US.fl_str_mv Development and characterization of Anti-VLA4 Monoclonal Antibody as a potential biopharmaceutical for the treatment of Multiple Sclerosis
title Development and characterization of Anti-VLA4 Monoclonal Antibody as a potential biopharmaceutical for the treatment of Multiple Sclerosis
spellingShingle Development and characterization of Anti-VLA4 Monoclonal Antibody as a potential biopharmaceutical for the treatment of Multiple Sclerosis
Castro, Vitória Fernandes de
Esclerose Múltipla
Bioterapêutico
Anticorpos Monoclonais
Multiple Sclerosis
Biotherapeutic
Monoclonal Antibodies
Esclerose Múltipla
Anticorpos Monoclonais
title_short Development and characterization of Anti-VLA4 Monoclonal Antibody as a potential biopharmaceutical for the treatment of Multiple Sclerosis
title_full Development and characterization of Anti-VLA4 Monoclonal Antibody as a potential biopharmaceutical for the treatment of Multiple Sclerosis
title_fullStr Development and characterization of Anti-VLA4 Monoclonal Antibody as a potential biopharmaceutical for the treatment of Multiple Sclerosis
title_full_unstemmed Development and characterization of Anti-VLA4 Monoclonal Antibody as a potential biopharmaceutical for the treatment of Multiple Sclerosis
title_sort Development and characterization of Anti-VLA4 Monoclonal Antibody as a potential biopharmaceutical for the treatment of Multiple Sclerosis
author Castro, Vitória Fernandes de
author_facet Castro, Vitória Fernandes de
Aquino, Carolina Lessa
Lima, Erykson
Chaves, Beatriz
Reis, Rafaella
Almeida, Vinícius Cotta de
Esteves, Gabriela Santos
Medeiros, Marco Alberto
author_role author
author2 Aquino, Carolina Lessa
Lima, Erykson
Chaves, Beatriz
Reis, Rafaella
Almeida, Vinícius Cotta de
Esteves, Gabriela Santos
Medeiros, Marco Alberto
author2_role author
author
author
author
author
author
author
dc.contributor.author.fl_str_mv Castro, Vitória Fernandes de
Aquino, Carolina Lessa
Lima, Erykson
Chaves, Beatriz
Reis, Rafaella
Almeida, Vinícius Cotta de
Esteves, Gabriela Santos
Medeiros, Marco Alberto
dc.subject.other.en_US.fl_str_mv Esclerose Múltipla
Bioterapêutico
Anticorpos Monoclonais
topic Esclerose Múltipla
Bioterapêutico
Anticorpos Monoclonais
Multiple Sclerosis
Biotherapeutic
Monoclonal Antibodies
Esclerose Múltipla
Anticorpos Monoclonais
dc.subject.en.en_US.fl_str_mv Multiple Sclerosis
Biotherapeutic
Monoclonal Antibodies
dc.subject.decs.en_US.fl_str_mv Esclerose Múltipla
Anticorpos Monoclonais
description Apresentador do material: Vitória Fernandes de Castro Tipo de material apresentado: Pôster
publishDate 2023
dc.date.accessioned.fl_str_mv 2023-04-24T14:04:43Z
dc.date.available.fl_str_mv 2023-04-24T14:04:43Z
dc.date.issued.fl_str_mv 2023
dc.type.status.fl_str_mv info:eu-repo/semantics/publishedVersion
dc.type.driver.fl_str_mv info:eu-repo/semantics/conferenceObject
format conferenceObject
status_str publishedVersion
dc.identifier.citation.fl_str_mv CASTRO, V. F. de et al. Development and characterization of Anti-VLA4 Monoclonal Antibody as a potential biopharmaceutical for the treatment of Multiple Sclerosis. In: INTERNATIONAL SYMPOSIUM ON IMMUNOBIOLOGICALS, 7., 2023, Rio de Janeiro. Annals of the Symposium: building pathways to accelerated the development of the national tecnhnological innovation ecosystem. Rio de Janeiro: Instituto de Tecnologia em Imunobiológicos, 2023. p. 42.
dc.identifier.uri.fl_str_mv https://www.arca.fiocruz.br/handle/icict/57932
dc.identifier.doi.none.fl_str_mv 10.35259/isi.2023_57932
identifier_str_mv CASTRO, V. F. de et al. Development and characterization of Anti-VLA4 Monoclonal Antibody as a potential biopharmaceutical for the treatment of Multiple Sclerosis. In: INTERNATIONAL SYMPOSIUM ON IMMUNOBIOLOGICALS, 7., 2023, Rio de Janeiro. Annals of the Symposium: building pathways to accelerated the development of the national tecnhnological innovation ecosystem. Rio de Janeiro: Instituto de Tecnologia em Imunobiológicos, 2023. p. 42.
10.35259/isi.2023_57932
url https://www.arca.fiocruz.br/handle/icict/57932
dc.language.iso.fl_str_mv eng
language eng
dc.rights.driver.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.source.none.fl_str_mv reponame:Repositório Institucional da FIOCRUZ (ARCA)
instname:Fundação Oswaldo Cruz (FIOCRUZ)
instacron:FIOCRUZ
instname_str Fundação Oswaldo Cruz (FIOCRUZ)
instacron_str FIOCRUZ
institution FIOCRUZ
reponame_str Repositório Institucional da FIOCRUZ (ARCA)
collection Repositório Institucional da FIOCRUZ (ARCA)
bitstream.url.fl_str_mv https://www.arca.fiocruz.br/bitstream/icict/57932/1/license.txt
https://www.arca.fiocruz.br/bitstream/icict/57932/2/Anais7thISI2023_42.pdf
bitstream.checksum.fl_str_mv 8a4605be74aa9ea9d79846c1fba20a33
65f50a1690fe13e05b6a0fd850c93ccb
bitstream.checksumAlgorithm.fl_str_mv MD5
MD5
repository.name.fl_str_mv Repositório Institucional da FIOCRUZ (ARCA) - Fundação Oswaldo Cruz (FIOCRUZ)
repository.mail.fl_str_mv repositorio.arca@fiocruz.br
_version_ 1798324919935696896

Registros relacionados